Managing bevacizumab-related toxicities in patients with colorectal cancer

Journal of Supportive Oncology

Volumn 7, Issue 6, 2009, Pages 245-251

  Saif, M Wasif ^a,b  

^a GI Cancers Program   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLACEBO; WARFARIN;

ABDOMINAL ABSCESS; ARTERY THROMBOSIS; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CANCER PATIENT; CARCINOMATOSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLON PERFORATION; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FISTULA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; NEPHROTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRACTICE GUIDELINE; PROTEINURIA; SMALL INTESTINE PERFORATION; STOMACH ULCER; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; THROMBOEMBOLISM;

EID: 73449122638     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.[15175435]
2. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE study. J Clin Oncol 2006;24(18S):3510.
3. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/nO16966, a randomized phase III trial in firstline metastatic colorectal cancer. J Clin Oncol 2007;25(18S):4028.
4. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.[15867200]
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.[15908660]
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005;23(16S):2.
7. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the uS (BRiTE). J Clin Oncol 2006;24(18S):3536.
8. Van Cutsem E, Michael M, Berry S, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mCRC: first BEAT trial. 2006 Gastrointestinal Cancers Symposium. Abstract 250.
9. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-566.[16774493]
10. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech; 2006.
11. Scappaticci F, Fehrenbacher L, Cartwright T, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. J Clin Oncol 2004;22(14S):3530.
12. Berry S, Michael M, Kretzschmar A, et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. 2006 Gastrointestinal Cancers Symposium. Abstract 245.
13. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006;24(18S):3535.
14. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-1869.[17356952]
15. Gray R, Giantonio BJ, O'Dwyer PJ, et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: the Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc Am Soc Clin Oncol 2003;22:825.
16. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23(16S):3019.
17. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2005;23(16S):3554.
18. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005;23(16S):4.
19. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982.[16514715]